Assessment of proteolytic degradation of the basement membrane: A fragment of type IV collagen as a biochemical marker for liver fibrosis

Fibrogenesis and Tissue Repair

Volumn 4, Issue 1, 2011, Pages

  Veidal, Sanne S ^a,b   Karsdal, Morten A ^a,b   Nawrocki, Arkadiusz ^b   Larsen, Martin R ^b   Dai, Yueqin ^c   Zheng, Qinlong ^c   Hägglund, Per ^d   Vainer, Ben ^e   Skjøt Arkil, Helene ^a,b   Leeming, Diana J ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Zhongguancun Life Science Park   (China)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Basement membrane; Biochemical marker; Extracellular matrix; Liver fibrosis; Matrix metalloproteinase 9; Neoepitope; Protease cleaved fragment; Type iv collagen

Indexed keywords

CARBON TETRACHLORIDE; COLLAGEN TYPE 4; EPITOPE; GELATINASE B; NEOEPITOPE; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BILE DUCT LIGATION; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

EID: 80054983554     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-4-22     Document Type: Article

References (34)

1. Friedman SL. Liver fibrosis: from bench to bedside. J Hepatol 2003, 38(Suppl 1):S38-S53.
2. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007, 381:107-113. 10.1016/j.cca.2007.02.038, 17399697.
3. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
4. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986, 1:523-525.
5. Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers 2010, 28:15-28.
6. Rowe RG, Weiss SJ. Breaching the basement membrane: who, when and how?. Trends Cell Biol 2008, 18:560-574. 10.1016/j.tcb.2008.08.007, 18848450.
7. Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases: molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993, 268:26033-26036.
8. Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 2008, 4:24-37. 10.1038/ncpneph0671, 18094725.
9. Van Agtmael T, Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue Res 2010, 339:167-188. 10.1007/s00441-009-0866-y, 19756754.
10. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis: a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007, 46:955-975. 10.1016/j.jhep.2007.02.003, 17383048.
11. Kirimlioglu H, Kirimlioglu V, Yilmaz S. Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation. Transplant Proc 2008, 40:3574-3577. 10.1016/j.transproceed.2008.09.033, 19100442.
12. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009, 14:181-202. 10.1080/13547500902777608, 19399662.
13. Combet C, Blanchet C, Geourjon C, Deléage G. NPS@: network protein sequence analysis. Trends Biochem Sci 2000, 25:147-150. 10.1016/S0968-0004(99)01540-6, 10694887.
14. Gefter ML, Margulies DH, Scharff MD. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977, 3:231-236. 10.1007/BF01551818, 605383.
15. Segovia-Silvestre T, Reichenbach V, Fernández-Varo G, Vassiliadis E, Barascuk N, Morales-Ruiz M, Karsdal MA, Jiménez W. Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair 2011, 4:19. 10.1186/1755-1536-4-19, 3170588, 21813019.
16. Clariá J, Jiménez W. Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. In The Liver and the Kidney 1999, 379-396. Boston: Blackwell Science.
17. Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jiménez W. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008, 324:475-483. 2887659, 18029545.
18. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006, 10:76-99. 10.1111/j.1582-4934.2006.tb00292.x, 16563223.
19. Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001, 16:777-781. 10.1046/j.1440-1746.2001.02515.x, 11446886.
20. Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol 2000, 32:325-330. 10.1016/S0168-8278(00)80079-3, 10707874.
21. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, Zheng Q, Xing R, Cao Y, Rasmussen LM, Karsdal MA. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010, 43:899-904. 10.1016/j.clinbiochem.2010.03.012, 20380828.
22. Vassiliadis E, Veidal SS, Simonsen H, Larsen DV, Vainer B, Chen X, Zheng Q, Karsdal MA, Leeming DJ. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 2011, 16:426-433. 10.3109/1354750X.2011.584131, 21612338.
23. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 2010, 3:5. 10.1186/1755-1536-3-5, 2860343, 20359335.
24. Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, Klickstein L, Larsen MR, Qvist P, Christiansen C, Vainer B, Karsdal MA. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 2010, 30:1293-1304. 10.1111/j.1478-3231.2010.02309.x, 20666994.
25. Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, Henriksen K, Zheng Q, Barkholt V, Riis BJ, Byrjalsen I, Qvist P, Karsdal MA. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP): assessment of corresponding epitopes. Clin Biochem 2010, 43:1249-1256. 10.1016/j.clinbiochem.2010.07.025, 20709044.
26. Vassiliadis E, Larsen DV, Clausen RE, Veidal SS, Barascuk N, Larsen L, Simonsen H, Silvestre TS, Hansen C, Overgaard T, Leeming DJ, Karsdal MA. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark Insights 2011, 6:49-58. 3076019, 21499440.
27. Vassiliadis E, Veidal SS, Barascuk N, Mullick JB, Clausen RE, Larsen L, Simonsen H, Larsen DV, Bay-Jensen AC, Segovia-Silvestre T, Leeming DJ, Karsdal MA. Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol 2011, 11:6. 10.1186/1471-5945-11-6, 3072322, 21447148.
28. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007, 11:1031-1051. 10.1111/j.1582-4934.2007.00092.x, 17979881.
29. Hsu CC, Lai SC. Matrix metalloproteinase-2, -9 and -13 are involved in fibronectin degradation of rat lung granulomatous fibrosis caused by Angiostrongylus cantonensis. Int J Exp Pathol 2007, 88:437-443. 10.1111/j.1365-2613.2007.00554.x, 18039280.
30. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998, 273:32347-32352. 10.1074/jbc.273.48.32347, 9822715.
31. Gioia M, Fasciglione GF, Monaco S, Iundusi R, Sbardella D, Marini S, Tarantino U, Coletta M. pH dependence of the enzymatic processing of collagen I by MMP-1 (fibroblast collagenase), MMP-2 (gelatinase A), and MMP-14 ectodomain. J Biol Inorg Chem 2010, 15:1219-1232. 10.1007/s00775-010-0680-8, 20549272.
32. Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999, 99:2503-2509.
33. Charni-Ben TN, Desmarais S, Bay-Jensen AC, Delaissé JM, Percival MD, Garnero P. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage 2008, 16:1183-1191. 10.1016/j.joca.2008.02.008, 18403221.
34. Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol 1996, 24:148-154. 10.1016/S0168-8278(96)80023-7, 8907567.